YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - Today's top biotech gainers include Zhengye Biotechnology, a veterinary vaccine manufacturer, which surged, easing Nasdaq delisting concerns; Advanced Biomed, which gained after withdrawing its planned U.S. securities offering…
(RTTNews) - Armata Pharmaceuticals, Inc. (ARMP), a late clinical-stage biotechnology company developing pathogen-specific bacteriophage therapeutics, announced that the U.S. FDA has agreed to its Initial Pediatric Study Plan (iPSP) for AP-…
Armata Pharmaceuticals (ARMP [https://seekingalpha.com/symbol/ARMP]) traded higher on Tuesday after the Department of Defense provided the company with $2.5M in additional funding to help advance its lead program, an antibacterial agent id…
Armata Pharmaceuticals Inc. (NYSE:ARMP) is one of the high-growth micro-cap stocks to buy now. On May 7, Armata Pharmaceuticals Inc. (NYSE:ARMP) achieved a significant milestone when the U.S Food and Drug Administration granted Fast Track…
Innoviva, Inc. (NASDAQ:INVA) is one of the best small-cap value stocks to buy. On April 8, Cantor Fitzgerald reiterated an Overweight rating on Innoviva Inc. (NASDAQ:INVA) and a $32 price target. The research firm remains confident about t…
LOS ANGELES, April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacterioph…
[Historic buildings of Wall Street in the financial district of lower Manhattan, New York City] deberarr U.S. stocks closed lower on Friday and ended lower for a fourth consecutive week as oil sustained higher prices despite efforts to min…
Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts.H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod Armata Pharmaceuticals, Inc. (N…
Exact Sciences (EXAS) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to a loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items.…
Key Points - GAAP revenue was $2.2 million, outpacing the $1.38 million GAAP consensus estimate due to strong grant and award funding. - Net loss widened significantly to $0.45 per share (GAAP). - Armata achieved a major milestone with pos…
Investing.com - Armata Pharma (NYSE: ARMP) reported second quarter EPS of $-0.450, $0.06 worse than the analyst estimate of $-0.390. Revenue for the quarter came in at $2.17M versus the consensus estimate of $1.38M. Armata Pharma’s stock p…
Received GSK royalties of $57.0 million and net product revenues of $13.7 million in the third quarter of 2023 Launched first-in-class therapy XACDURO® for treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacter…
Received GSK royalties of $65.7 million, net product revenues of $15.7 million and license revenue of $3.0 million in the second quarter of 2023 Received FDA approval for XACDURO® for treatment of hospital-acquired bacterial pneumonia and…
Signs new $25 million credit agreement and extension of existing secured convertible credit agreement Appoints world‐renowned healthcare leader Dr. Deborah L. Birx as Chief Executive Officer MARINA DEL REY, Calif., July 11, 2023 /PRNewswir…
MARINA DEL REY, Calif., May 31, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant a…
MARINA DEL REY, Calif., May 11, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant a…
MARINA DEL REY, Calif., March 16, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant…
AP-PA02 is well-tolerated and data supports progression to Phase 2b Also announces first subject dosed in Phase 2 'Tailwind' clinical trial of inhaled AP-PA02 in patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) NCFB represents Armat…
MARINA DEL REY, Calif., Jan. 10, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant…
MARINA DEL REY, Calif., Dec. 22, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant…
The price trend for Armata Pharmaceuticals, Inc. (ARMP) has been bearish lately and the stock has lost 14.5% over the past two weeks. However, the formation of a hammer chart pattern in its last trading session indicates that the stock cou…
Armata Pharmaceuticals, Inc. (ARMP) has been on a downward spiral lately with significant selling pressure. After declining 35.3% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold terri…
MARINA DEL REY, Calif., Nov. 28, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant…
The price trend for Armata Pharmaceuticals, Inc. (ARMP) has been bearish lately and the stock has lost 5.6% over the past four weeks. However, the formation of a hammer chart pattern in its last trading session indicates that the stock cou…
MARINA DEL REY, Calif., Nov. 9, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant a…
MARINA DEL REY, Calif., Aug. 11, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant…
Second indication for AP-SA02 which targets Staphylococcus aureus including MRSA Potential to significantly improve PJI patient outcomes Expands Armata's pursuit of phage therapy as a solution for difficult-to-treat infections MARINA DEL R…
Study conducted in partnership with the US Department of Defense MARINA DEL REY, Calif., May 23, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathog…
MARINA DEL REY, Calif, May 12, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant an…
Royalties increased by 5% to $93.5 million in the first quarter of 2022, compared to the same quarter in 2021. Issued $261.0 million convertible senior notes due 2028 and repurchased a portion of the convertible subordinated notes due 2023…
MARINA DEL REY, Calif., March 31, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant…
Armata Pharmaceuticals, Inc. (ARMP) closed the last trading session at $5.03, gaining 0.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guid…
MARINA DEL REY, Calif., March 17, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant…
HatchSpaces, NexCore Group and Nuveen Real Estate are converting a 56,300-square-foot industrial building to a biomanufacturing facility for Armata’s new base.
Upon initiation in 2022, the trial will represent the company's third clinical program in a distinct indication MARINA DEL REY, Calif., Feb. 22, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Comp…
MARINA DEL REY, Calif., Feb. 17, 2022 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant…